These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1794817)

  • 1. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
    Schmidt J; Schmitt C; Hockwin O
    Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No lens changes caused by simvastatin results from a prospective drug safety study.
    Schmidt J; Schmitt C; Hockwin O
    Lens Eye Toxic Res; 1990; 7(3-4):643-50. PubMed ID: 2100182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
    Perrot JL; Guy C; Bour Guichenez G; Amigues O; Servoz J; Cambazard F
    Ann Dermatol Venereol; 1994; 121(11):817-9. PubMed ID: 7631993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin.
    Schmitt C; Schmidt J; Hockwin O
    Lens Eye Toxic Res; 1990; 7(3-4):631-42. PubMed ID: 2129220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pravastatin, simvastatin, and lovastatin for lowering serum cholesterol concentrations.
    Med Lett Drugs Ther; 1992 Jun; 34(872):57-8. PubMed ID: 1593973
    [No Abstract]   [Full Text] [Related]  

  • 7. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up.
    Behrens-Baumann W; Thiery J; Wieland E; Fieseler HG; Seidel D
    Arzneimittelforschung; 1992 Aug; 42(8):1023-4. PubMed ID: 1418074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
    Golay A; Lehmann T; James R; Pometta D
    Schweiz Med Wochenschr; 1993 Aug; 123(33):1553-8. PubMed ID: 8372340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.
    Eckernäs SA; Roos BE; Kvidal P; Eriksson LO; Block GA; Neafus RP; Haigh JR
    Br J Clin Pharmacol; 1993 Mar; 35(3):284-9. PubMed ID: 8471404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.
    Behrens-Baumann W; Morawietz A; Thiery J; Creutzfeldt C; Seidel D
    Lens Eye Toxic Res; 1989; 6(1-2):331-7. PubMed ID: 2488025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects and side effects of a 1-year treatment of primary hypercholesterolemia with simvastatin].
    Brocard JJ; Keller U; Oberhänsli A; Riesen WF
    Schweiz Med Wochenschr; 1991 Jun; 121(26):977-83. PubMed ID: 1862314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular drug safety and HMG-CoA-reductase inhibitors.
    Schmidt J; Schmitt C; Hockwin O; Paulus U; von Bergmann K
    Ophthalmic Res; 1994; 26(6):352-60. PubMed ID: 7715916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of a selective inhibitor of cholesterol synthesis: pravastatin].
    Alessandri C; Peverini F
    Minerva Med; 1992 Nov; 83(11):677-93. PubMed ID: 1461539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
    Branchi A; Rovellini A; Sommariva D; Gugliandolo AG; Fasoli A
    Thromb Haemost; 1993 Aug; 70(2):241-3. PubMed ID: 8236126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of clinical trials comparing HMG-CoA reductase inhibitors.
    Illingworth DR; Tobert JA
    Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance].
    Panuccio D; Trabatti MR; Romani A
    Clin Ter; 1994 May; 144(5):419-24. PubMed ID: 7924180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.